• Home (current)
  • La Società
    Chi siamo Soci collettivi Collaborazioni tecniche Bilancio societario
  • Sezioni Regionali
  • Convegni e Formazione
    Eventi SINU Altri eventi Eventi patrocinati
  • Newsletters
  • Cerca
  • Come iscriversi
  • Area Soci:
  • Registrati
  • Login
  • English version
  • Passa al contenuto principale

SINU

Società Italiana di Nutrizione Umana

EFSA – Sicurezza del cannabidiolo come novel food

The European Commission has determined that cannabidiol (CBD) can be considered as a novel food (NF), and currently, 19 applications are under assessment at EFSA. While assessing these, it has become clear that there are knowledge gaps that need to be addressed before a conclusion on the safety of CBD can be reached. Consequently, EFSA has issued this statement, summarising the state of knowledge on the safety of CBD consumption and highlighting areas where more data are needed. Literature searches for both animal and human studies have been conducted to identify safety concerns. Many human studies have been carried out with Epidyolex®, a CBD drug authorised to treat refractory epilepsies. In the context of medical conditions, adverse effects are tolerated if the benefit outweighs the adverse effect. This is, however, not acceptable when considering CBD as a NF. Furthermore, most of the human data referred to in the CBD applications investigated the efficacy of Epidyolex (or CBD) at therapeutic doses. No NOAEL could be identified from these studies. Given the complexity and importance of CBD receptors and pathways, interactions need to be taken into account when considering CBD as a NF. The effects on drug metabolism need to be clarified. Toxicokinetics in different matrices, the half‐life and accumulation need to be examined. The effect of CBD on liver, gastrointestinal tract, endocrine system, nervous system and on psychological function needs to be clarified. Studies in animals show significant reproductive toxicity, and the extent to which this occurs in humans generally and in women of child‐bearing age specifically needs to be assessed. Considering the significant uncertainties and data gaps, the Panel concludes that the safety of CBD as a NF cannot currently be established.

Consulta il documento


HOME

LARN IV revisione
NMCD
Meno sale più salute
Come iscriversi
Questionari
Il Punto su…
Congresso SINU 2019
Documenti SINU

LA SOCIETA'

Chi siamo
Soci collettivi
Collaborazioni tecniche
Biancio societario

FORMAZIONE

Eventi SINU
Altri eventi
Eventi patrocinati

NEWS

In evidenza
News recenti

CONTATTI

Sezioni regionali
Gruppi di lavoro
Privacy policy

SEGRETERIA SINU

c/o BioMedia srl
via Libero Temolo 4
20126 Milano
02 45498282
02 45498199
info@sinu.it

Copyright © 2019 SINU - Tutti i diritti riservati.


Un progetto realizzato da: BioMedia srl.

Recupera password

Presto Disponibile